Topical corticosteroids remain first-line therapy for most inflammatory dermatoses, from eczema to psoriasis to contact dermatitis. But the same drug class that clears a flare can also cause skin atrophy, striae, and rebound if the potency doesn't match the site and duration of use. Reviewing potency alongside diagnosis is one of the highest-value checks a pharmacist can make.
The Seven-Class Potency System
In the US, topical corticosteroids are grouped into seven potency classes, from Class I (ultra-high) to Class VII (low). Potency depends on the specific molecule, its concentration, and its vehicle, not the drug name alone; the same molecule can shift potency class depending on formulation.
| Class | Potency | Representative agents |
|---|---|---|
| I | Ultra-high | Clobetasol propionate 0.05%, betamethasone dipropionate 0.05% (augmented) |
| II–III | High | Fluocinonide 0.05%, betamethasone dipropionate 0.05% |
| IV–V | Medium | Triamcinolone acetonide 0.1%, fluticasone propionate 0.05% |
| VI | Low-medium | Desonide 0.05%, alclometasone dipropionate 0.05% |
| VII | Low | Hydrocortisone 1–2.5% |
Site-Based Selection
Skin thickness and barrier integrity vary enormously by body site, and absorption varies with it. As a general framework:
- Thin-skin, high-absorption areas (face, eyelids, genitals, intertriginous folds) generally call for low-to-medium potency, given the higher risk of atrophy and systemic absorption in these regions.
- Thick-skin, low-absorption areas (palms, soles, scalp, thick psoriatic plaques) often require higher potency to achieve adequate penetration and effect.
- Trunk and extremities typically fall in the medium-potency range for most inflammatory conditions.
Duration and Tapering
Extended use of high- or ultra-high-potency agents carries real risk: cutaneous atrophy, telangiectasia, striae, and tachyphylaxis (a diminishing response over time). Common strategies to mitigate this include stepping down to a lower potency class as a flare resolves, pulse or weekend-only dosing for maintenance, and time-limited courses with a defined follow-up point rather than open-ended refills.
Systemic Absorption Considerations
Occlusion (from diapers, wraps, or naturally occlusive skin folds) meaningfully increases percutaneous absorption. Pediatric patients have a higher surface-area-to-body-weight ratio than adults, which increases systemic exposure risk from the same topical dose, an important consideration when a prescription seems disproportionate to a small treatment area.
Where Pharmacists Add Value
- Confirming that prescribed potency is appropriate for the diagnosis and treatment site
- Flagging refill patterns that suggest a high-potency agent is being used longer, or on a broader area, than intended
- Counseling on application technique, including the fingertip unit concept for estimating an appropriate amount
- Watching for early signs of atrophy or steroid dependence during refill conversations
This is an educational overview and does not constitute medical or pharmaceutical advice, nor a substitute for full prescribing information or clinical judgment. Potency selection should always follow the prescriber's diagnosis and treatment plan.